Despite the demonstrated anti-inflammatory effects of PPAR-gamma activators [8], the favorable metabolic effects of RGZ were not accompanied by amelioration of adipose tissue inflammation induced by HFD and obesity. Here, PPARG is linked to obesity disorder.